Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes

Mark C. Gillies; Richard Walton; Judy M. Simpson; Jennifer J. Arnold; Robyn H. Guymer; Ian L. McAllister; Alex P. Hunyor; Rohan W. Essex; Nigel Morlet; Daniel Barthelmes

doi:10.1167/iovs.13-11993

Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes

Mark C. Gillies, Richard Walton, Judy M. Simpson, Jennifer J. Arnold, Robyn H. Guymer, Ian L. McAllister, Alex P. Hunyor, Rohan W. Essex, Nigel Morlet, Daniel Barthelmes

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

Abstract

PURPOSE. We report the 12-month outcomes of 1140 treatment-naïve eyes with exudative agerelated macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice. METHODS. Index visit characteristics, such as lesion type and size, visual acuity (VA, in Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments, outcomes (VA, lesion activity status) and ocular adverse events were recorded in a prospectively designed electronic database. Index visit characteristics associated with the 12-month VA outcome were identified using mixed effects linear regression. RESULTS. Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95% confidence interval [CI], 3.4-6.1) with a mean of 7.0 injections. No significant difference was found in change in VA, or number of injections by type or size of the lesion. Median time to inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment occurred in 1 case from a total of 9162 injections. CONCLUSIONS. These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet AMD when used in routine clinical practice.

Original language	English
Pages (from-to)	5754-5760
Number of pages	7
Journal	Investigative Ophthalmology and Visual Science
Volume	54
Issue number	8
DOIs	https://doi.org/10.1167/iovs.13-11993
Publication status	Published - 2013

Access to Document

10.1167/iovs.13-11993

Cite this

Gillies, M. C., Walton, R., Simpson, J. M., Arnold, J. J., Guymer, R. H., McAllister, I. L., Hunyor, A. P., Essex, R. W., Morlet, N., & Barthelmes, D. (2013). Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes. Investigative Ophthalmology and Visual Science, 54(8), 5754-5760. https://doi.org/10.1167/iovs.13-11993

@article{2986e86b20a04bb080186c813da397fe,

title = "Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-na{\"i}ve eyes",

abstract = "PURPOSE. We report the 12-month outcomes of 1140 treatment-na{\"i}ve eyes with exudative agerelated macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice. METHODS. Index visit characteristics, such as lesion type and size, visual acuity (VA, in Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments, outcomes (VA, lesion activity status) and ocular adverse events were recorded in a prospectively designed electronic database. Index visit characteristics associated with the 12-month VA outcome were identified using mixed effects linear regression. RESULTS. Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95% confidence interval [CI], 3.4-6.1) with a mean of 7.0 injections. No significant difference was found in change in VA, or number of injections by type or size of the lesion. Median time to inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment occurred in 1 case from a total of 9162 injections. CONCLUSIONS. These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet AMD when used in routine clinical practice.",

keywords = "Anti-VEGF, Neovascular age-related macular degeneration, Observational study",

author = "Gillies, {Mark C.} and Richard Walton and Simpson, {Judy M.} and Arnold, {Jennifer J.} and Guymer, {Robyn H.} and McAllister, {Ian L.} and Hunyor, {Alex P.} and Essex, {Rohan W.} and Nigel Morlet and Daniel Barthelmes",

year = "2013",

doi = "10.1167/iovs.13-11993",

language = "English",

volume = "54",

pages = "5754--5760",

journal = "Investigative Ophthalmology and Visual Science",

issn = "0146-0404",

publisher = "Association for Research in Vision and Ophthalmology Inc.",

number = "8",

}

TY - JOUR

T1 - Prospective audit of exudative age-related macular degeneration

T2 - 12-month outcomes in treatment-naïve eyes

AU - Gillies, Mark C.

AU - Walton, Richard

AU - Simpson, Judy M.

AU - Arnold, Jennifer J.

AU - Guymer, Robyn H.

AU - McAllister, Ian L.

AU - Hunyor, Alex P.

AU - Essex, Rohan W.

AU - Morlet, Nigel

AU - Barthelmes, Daniel

PY - 2013

Y1 - 2013

N2 - PURPOSE. We report the 12-month outcomes of 1140 treatment-naïve eyes with exudative agerelated macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice. METHODS. Index visit characteristics, such as lesion type and size, visual acuity (VA, in Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments, outcomes (VA, lesion activity status) and ocular adverse events were recorded in a prospectively designed electronic database. Index visit characteristics associated with the 12-month VA outcome were identified using mixed effects linear regression. RESULTS. Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95% confidence interval [CI], 3.4-6.1) with a mean of 7.0 injections. No significant difference was found in change in VA, or number of injections by type or size of the lesion. Median time to inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment occurred in 1 case from a total of 9162 injections. CONCLUSIONS. These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet AMD when used in routine clinical practice.

AB - PURPOSE. We report the 12-month outcomes of 1140 treatment-naïve eyes with exudative agerelated macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice. METHODS. Index visit characteristics, such as lesion type and size, visual acuity (VA, in Logarithm of the Minimal Angle of Resolution [logMAR] letters), as well as treatments, outcomes (VA, lesion activity status) and ocular adverse events were recorded in a prospectively designed electronic database. Index visit characteristics associated with the 12-month VA outcome were identified using mixed effects linear regression. RESULTS. Mean change in VA in the cohort after 12 months was +4.7 logMAR letters (95% confidence interval [CI], 3.4-6.1) with a mean of 7.0 injections. No significant difference was found in change in VA, or number of injections by type or size of the lesion. Median time to inactivation of lesions was 194 days. VA at the index visit was the strongest predictor for the 12-month outcomes. Infectious endophthalmitis occurred in 2 cases, and retinal detachment occurred in 1 case from a total of 9162 injections. CONCLUSIONS. These findings indicate that VEGF inhibitors can achieve reasonably good outcomes for wet AMD when used in routine clinical practice.

KW - Anti-VEGF

KW - Neovascular age-related macular degeneration

KW - Observational study

UR - http://www.scopus.com/inward/record.url?scp=84883213217&partnerID=8YFLogxK

U2 - 10.1167/iovs.13-11993

DO - 10.1167/iovs.13-11993

M3 - Article

SN - 0146-0404

VL - 54

SP - 5754

EP - 5760

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

IS - 8

ER -

Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes

Abstract

Access to Document

Other files and links

Fingerprint

Cite this